



NATIONAL RESEARCH  
UNIVERSITY



# Work Programme 2012 COOPERATION

## Health

A. Mazurin

Centre for International Projects

Institute for Statistical Studies and Economics of Knowledge

# Objectives

Improving the health of European citizen and increasing competitiveness of European health-related industries and services, as well as addressing the socio-economic dimension of health care and global health issues.

To enable citizens to live longer independently in good health by increasing the average number of healthy life years by two in achieving this target:

- to improve the sustainability and efficiency of our social and healthcare systems
- to create an EU and global market for innovative products and services with new opportunities for EU business.

## CALL for proposals of 20 July 2011

Two two-stage calls:

### FP7-HEALTH-2012-INNOVATION-1

main call with an indicative budget of EUR 546 million with broader topics of which many are tailored for SME participation (bottom-up with a minimum percentage of EU funding requested going to SMEs)

### FP7-HEALTH-2012-INNOVATION-2

a pilot call with an indicative budget of 108 million EUR with specific conditions

# CALL for proposals of 20 July 2011

## HEALTH-2012-INNOVATION

Call identifier: FP7-HEALTH-2012-INNOVATION-1

Proposal submission and evaluation: two-stage procedure.

Date of publication: 20 July 2011

Deadline for stage 1 proposals: 04 October 2011 at 17:00:00 (Brussels local time)

Indicative budget: EUR 546 million



# 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

## 1.2 DETECTION, DIAGNOSIS AND MONITORING

The objectives are to develop visualisation, imaging, detection and analytical tools and technologies for biomedical research, for prediction, diagnosis, monitoring and prognosis of diseases, and for support and guidance of therapeutic interventions.

Indicative budget: 55 M€

Two-stage submission procedure

HEALTH.2012.1.2-1: Development of technologies with a view to patient group stratification for personalised medicine applications.



# 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

## 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS

The main focus is on transplantation, with subsidiary topics on international cooperation in stem cell research and targeted nucleic acid delivery. Topics are drafted in broad terms to encourage innovation.

Indicative budget: 42 M€

Two-stage submission procedure

HEALTH.2012.1.4-1: Innovative approaches to solid organ transplantation

HEALTH.2012.1.4-3: Innovative Strategies for translation of stem cell based therapies in regenerative medicine (European Union-Australia cooperation).

HEALTH.2012.1.4-4: Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach

## 2. TRANSLATING RESEARCH FOR HUMAN HEALTH

### 2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY

#### 2.1.1 LARGE-SCALE DATA GATHERING

Objective : to use high-throughput technologies to generate data for elucidating the function of genes and gene products in biological processes.

Topics focus on the clinical use of -omics approaches and the analysis of their outcomes.

##### 2.1.1-1 (A-C) – Omics for rare diseases

Indicative budget: 38 M€

Projects funded under this heading should contribute towards the ambitious 2020 goals of the International Rare Diseases Research Consortium (IRDiRC): 200 new therapies for rare diseases (orphan drugs) and diagnostics tests for all rare diseases.

This sub-area will be implemented via three topics:

- one support action (duration: six years),
- one collaborative project as a large-scale integrating project (duration: six years)
- and up to two collaborative projects, as large-scale integrating projects (duration: up to five years) can be funded.

## 2. TRANSLATING RESEARCH FOR HUMAN HEALTH

HEALTH.2012.2.1.1-2: Validation of -omics-based biomarkers for diseases affecting the elderly.

HEALTH.2012.2.1.1-3: Statistical methods for collection and analysis of -omics data.

Indicative budget: 39 M€

### 2.1.2 SYSTEMS BIOLOGY

Indicative budget: 70 M€

The focus of this area is to apply multidisciplinary research that will integrate a wide variety of biological data and will develop and apply system approaches to understand and model biological processes in all relevant organisms and at all levels of organisation.

HEALTH.2012.2.1.2-1: Systems medicine: SME-driven research applying systems biology approaches to address medical and clinical needs.

HEALTH.2012.2.1.2-2: Systems medicine: Applying systems biology approaches for understanding multifactorial human diseases and their co-morbidities.

HEALTH.2012.2.1.2-3: Preparing for the future research and innovation activities in systems medicine.



## 2. TRANSLATING RESEARCH FOR HUMAN HEALTH

### 2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING

#### 2.2.2 Human development and ageing

Indicative budget: 36 M€

The focus on: the use and application of -omics knowledge and tools to gain a clear understanding of the fundamental mechanisms of human ageing and on the detection, monitoring and development of innovative therapeutic tools for age-related diseases as well as the optimisation of treatment for elderly patients.

HEALTH.2012.2.2.2-1: Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases.

HEALTH.2012.2.2.2.-2: Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases.

## 2. TRANSLATING RESEARCH FOR HUMAN HEALTH

### 2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

The aim of this area is to confront major threats to public health with emphasis on HIV/AIDS, malaria, tuberculosis, hepatitis, neglected infectious diseases, emerging epidemics and antimicrobial drug resistance, including fungal pathogens.

#### HEALTH.2012.2.3.0-2: ERA-NET on infectious diseases. FP7-ERANET-2012-RTD

The proposed new ERA-NET could build upon the previous ERA-NET PathoGenoMics and capitalise on its achievements.

#### 2.3.2 HIV/AIDS, malaria and tuberculosis

Indicative budget: 54 M€

Topics focus on: co-infection and co-morbidity, as well as on prevention and treatment for HIV/AIDS, malaria and tuberculosis.

HEALTH.2012.2.3.2-1: Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis.

HEALTH.2012.2.3.2-2: Co-morbidity between infectious and noncommunicable diseases.

HEALTH.2012.2.3.2-3: Prevention and treatment for HIV/AIDS, malaria and tuberculosis.

HEALTH.2012.2.3.2-4: Low-cost interventions for disease control in resource poor settings.

## 2. TRANSLATING RESEARCH FOR HUMAN HEALTH

### 2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

#### 2.4.3 Diabetes and obesity

Indicative budget: 36 M€

The focus on: developing and testing innovation in the field of diabetes management, as well as on investigator-driven clinical trials addressing informed clinical management for type 1 diabetes, particularly in childhood and adolescence.

HEALTH.2012.2.4.3-1: Innovative approach to manage diabetes.

HEALTH.2012.2.4.3-2: Investigator-driven clinical trials for type 1 diabetes research.

## 2. TRANSLATING RESEARCH FOR HUMAN HEALTH

### 2.4.4 Rare diseases

Indicative budget: 70 M€

The focus on: the preclinical and clinical development of orphan drugs, and on the conduction of observational trials for those rare diseases treated off-label, aiming to improve clinical practices in the management of these diseases.

HEALTH.2012.2.4.4-1: Preclinical and/or clinical development of substances with a clear potential as orphan drugs.

HEALTH.2012.2.4.4-2: Observational trials in rare diseases.

HEALTH.2012.2.4.4-3: Best practice and knowledge sharing in the clinical management of rare diseases.

### 2.4.5 Other chronic diseases

Indicative budget: 12 M€

The focus on: non-lethal diseases and chronic conditions with a high impact on the quality of life at old age such as functional and sensory impairment and chronic inflammatory diseases.

HEALTH.2012.2.4.5-2: Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system.



## 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS

### 3.2 QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTH CARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS Indicative budget: 39 M€

The focus on: health service delivery, health technology assessments, reimbursement systems and social innovation in ageing research.

Projects should contribute to the implementation of both, the European Innovation Partnership principles and measures to support the application of the cross-border directive.

HEALTH.2012.3.2-1: Improving the organisation of health service delivery.

HEALTH.2012.3.2-2: New methodologies for health technology assessment.

HEALTH.2012.3.2-3: Social innovation for active and healthy ageing.

### 3.4 INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS Indicative budget: 18 M€

The focus on: health systems/services research while at the same time strengthening research capacity building in terms of human resources.

HEALTH.2012.3.4-1: Research on health systems and services in low- and middleincome countries.

## 4. OTHER ACTIONS ACROSS THE HEALTH THEME

### 4.1 COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME

Indicative budget: 7 M€

The objective: to contribute to the implementation of the Framework programmes and the preparation of future European Union (Community) research and technological development policy.

The focus: on technology transfer and dissemination of results.

HEALTH.2012.4.1-1: Network to encourage knowledge transfer activity in FP-funded health research (especially in academic and governmental organisations).

HEALTH.2012.4.1-2: Training actions linked to intellectual property rights management and knowledge transfer.

HEALTH.2012.4.1-3: Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union.

HEALTH.2012.4.1-4: Communicating the benefits of European research to the general public.

HEALTH.2012.4.1-5: Preparing the future for health research and innovation.

HEALTH.2012.4.1-6: Setting healthrelated development goals beyond 2015.

# IMPLEMENTATION OF CALLS

## ELIGIBILITY CONDITIONS

Funding scheme	Minimum conditions
Collaborative Project	At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC
Coordination and Support Actions (coordinating action)	At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC
Coordination and Support Actions (supporting action)	At least 1 independent legal entity

### Specific conditions for this call:

Collaborative project for specific cooperation Action (SICA) dedicated to international cooperation partner countries, topic HEALTH.2012.3.4-1

At least 8 independent legal entities. Of these, 2 must be established in different MS or AC. The other 6 must be established in different international cooperation partner countries (ICPC)



# CALL for proposals of 20 July 2011

## FP7-HEALTH-2012-SMEs-FOR-INNOVATION

Call identifier: FP7-HEALTH-2012-INNOVATION-2

Proposal submission and evaluation: two-stage procedure.

Date of publication: 20 July 2011

Deadline for stage 1 proposals: 27 September 2011 at 17:00:00 (Brussels local time)

Indicative budget: EUR 108 million from the 2012 budget

**Participation is restricted** to 3-5 entities established in EU Member States and Associated Countries.

**Specific feature for this call:** This call is dedicated to a specific SME innovation initiative designed to encourage stronger SME efforts towards research and innovation. SMEs need to have a leading or coordinating role in the consortium and **50 % of EU funding requested going to SMEs or SMEs joint venture**. Expected project results should be of clear interest and potential benefit to SME(s).



## 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

### 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS

Indicative budget: 42 M€

HEALTH.2011.1.4-2: Medical technology for transplantation and bioartificial organs.

## 2. TRANSLATING RESEARCH FOR HUMAN HEALTH

### 2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

#### 2.3.0 Cross-cutting

Indicative budget: 36 M€

HEALTH.2012.2.3.0-1: Diagnostics for infectious diseases in humans.

### 2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

#### 2.4.5 Other chronic diseases

Indicative budget: 30 M€

HEALTH.2012.2.4.5-1: Technological approaches to combating sensory impairments.

## ELIGIBILITY CONDITIONS

Funding scheme	Minimum conditions
Collaborative Project	Number of participants: At least 3 and maximum 5 independent legal entities, each of which is established in a EU Member State or Associated Country, and at least 3 are established in 3 different MS or AC.

## Further information

- General information  
<http://cordis.europa.eu/fp7/health>
- Calls information  
[http://ec.europa.eu/research/participants/portal/page/fp7\\_calls](http://ec.europa.eu/research/participants/portal/page/fp7_calls)
- 2012 Work Programmes  
[http://cordis.europa.eu/fp7/wp-2012\\_en.html](http://cordis.europa.eu/fp7/wp-2012_en.html)
- NCP Health  
<http://fp7-health.ru/>  
Mr. Vsevolod Tkachuk, Ms. Elena Tarasova  
Lomonosovskiy prosp., 31, build 5, Moscow  
7 495 9328814  
7 499 7255547  
E-mail: [lenaronet@mail.ru](mailto:lenaronet@mail.ru); [mail@fp7-health.ru](mailto:mail@fp7-health.ru)



NATIONAL RESEARCH  
UNIVERSITY

Thank you  
for your attention!

